The impact of COVID-19 vaccine reactions on secondary vaccine hesitancy
Copyright © 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Primary and booster vaccinations are critical for mitigating COVID-19 transmission, morbidity, and mortality. Future booster vaccine campaigns rely on an increased understanding of vaccine hesitancy.
OBJECTIVE: To evaluate self-reported allergic and skin vaccine reactions as factors potentially associated with vaccine hesitancy in a nationwide vaccine allergy registry.
METHODS: Responses to survey questions concerning COVID-19 vaccine perceptions, coded from free text by 2 independent reviewers. Multivariable logistic regression models were used to determine the association between changed negative perception and respondent demographics, vaccination history, and reaction characteristics.
RESULTS: A total of 993 individuals (median of 46 years [IQR, 36-59], 88% female, 82% White) self-reported reactions to COVID-19 vaccination. Reactions included the following: delayed large local skin reaction (40%), hives/urticaria (32%), immediate large local skin reaction (3%), swelling (3%), anaphylaxis (2%), and other or unspecified (20%). Most respondents were initially unconcerned about the safety of COVID-19 vaccines (56%). After reactions, 401 of 993 (40%) report negative change in perception of vaccination, with more than half of these respondents (n = 211, 53%) citing their reasoning as a negative experience with adverse effects. Of 102 individuals asked about future vaccination, 79 (77%) indicated that they were unlikely or very unlikely to receive future COVID-19 vaccinations. Increased negative perception after reaction was associated with younger age, later COVID-19 vaccination dose number, and reaction type.
CONCLUSION: Our findings reveal that an individual's experience with allergic or cutaneous adverse effects after COVID-19 vaccination affects attitudes and decision-making regarding future vaccination, even in initially non-hesitant individuals. Further investigation of secondary vaccine hesitancy is necessary for adapting public health messaging to this important population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology - (2024) vom: 16. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Freeman, Esther E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.anai.2024.01.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36723324X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36723324X | ||
| 003 | DE-627 | ||
| 005 | 20240210233130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anai.2024.01.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM36723324X | ||
| 035 | |a (NLM)38232816 | ||
| 035 | |a (PII)S1081-1206(24)00010-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Freeman, Esther E |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of COVID-19 vaccine reactions on secondary vaccine hesitancy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Primary and booster vaccinations are critical for mitigating COVID-19 transmission, morbidity, and mortality. Future booster vaccine campaigns rely on an increased understanding of vaccine hesitancy | ||
| 520 | |a OBJECTIVE: To evaluate self-reported allergic and skin vaccine reactions as factors potentially associated with vaccine hesitancy in a nationwide vaccine allergy registry | ||
| 520 | |a METHODS: Responses to survey questions concerning COVID-19 vaccine perceptions, coded from free text by 2 independent reviewers. Multivariable logistic regression models were used to determine the association between changed negative perception and respondent demographics, vaccination history, and reaction characteristics | ||
| 520 | |a RESULTS: A total of 993 individuals (median of 46 years [IQR, 36-59], 88% female, 82% White) self-reported reactions to COVID-19 vaccination. Reactions included the following: delayed large local skin reaction (40%), hives/urticaria (32%), immediate large local skin reaction (3%), swelling (3%), anaphylaxis (2%), and other or unspecified (20%). Most respondents were initially unconcerned about the safety of COVID-19 vaccines (56%). After reactions, 401 of 993 (40%) report negative change in perception of vaccination, with more than half of these respondents (n = 211, 53%) citing their reasoning as a negative experience with adverse effects. Of 102 individuals asked about future vaccination, 79 (77%) indicated that they were unlikely or very unlikely to receive future COVID-19 vaccinations. Increased negative perception after reaction was associated with younger age, later COVID-19 vaccination dose number, and reaction type | ||
| 520 | |a CONCLUSION: Our findings reveal that an individual's experience with allergic or cutaneous adverse effects after COVID-19 vaccination affects attitudes and decision-making regarding future vaccination, even in initially non-hesitant individuals. Further investigation of secondary vaccine hesitancy is necessary for adapting public health messaging to this important population | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Strahan, Alexis G |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Liam R |e verfasserin |4 aut | |
| 700 | 1 | |a Judd, Allen D |e verfasserin |4 aut | |
| 700 | 1 | |a Samarakoon, Upeka |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Geoffrey |e verfasserin |4 aut | |
| 700 | 1 | |a King, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Blumenthal, Kimberly G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology |d 1995 |g (2024) vom: 16. Jan. |w (DE-627)NLM075127695 |x 1534-4436 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:16 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anai.2024.01.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 16 |c 01 | ||